MorphoSys to Effect 1:3 Stock Split on December 23, 2008

MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that
the 3-for-1 stock split of the MorphoSys share, which was resolved by
the Company's shareholders at the Annual Shareholder Meeting on May
14, 2008, will be implemented on December 23, 2008. The first day of
trading on a split-adjusted basis will be December 23, 2008.

By implementing the stock split, all existing non-par value shares of
MorphoSys AG with a current par-equivalent value of EUR 3.00 will be
divided into three shares each with a par-equivalent value of EUR
1.00, with a corresponding adjustment to the most recently quoted
price. The resulting changes to the Articles of Association have
been entered into the commercial register. Following the split, each
shareholder will automatically hold three shares for each share
previously held.

"We expect this stock split to increase accessibility of the stock to
various investors, which should ultimately improve the liquidity of
the MorphoSys share," explained Dave Lemus, Chief Financial Officer
of MorphoSys AG.

For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj,
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com

About MorphoSys:
MorphoSys is a publicly traded biotechnology company focused on the
generation of fully human antibodies as a means to discover and
develop innovative antibody-based drugs against life-threatening
diseases. MorphoSys's goal is to establish HuCAL as the technology of
choice for antibody generation in research, diagnostics and
therapeutic applications. The Company currently has therapeutic and
research alliances with the majority of the world's largest
pharmaceutical companies including Boehringer Ingelheim,
Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these
partnerships, more than 50 therapeutic antibody programs are ongoing
in which MorphoSys participates through exclusive license and
milestones payments as well as royalties on any end products.
Additionally, MorphoSys is active in the antibody research market
through its AbD Serotec business unit. The business unit has
operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.
(Oxford). For further information please visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG

This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2008. All rights reserved.